AJ-CISATRACURIUM SOLUTION

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

CISATRACURIUM (CISATRACURIUM BESYLATE)

제공처:

AGILA JAMP CANADA INC

ATC 코드:

M03AC11

INN (International Name):

CISATRACURIUM

복용량:

2MG

약제 형태:

SOLUTION

구성:

CISATRACURIUM (CISATRACURIUM BESYLATE) 2MG

관리 경로:

INTRAVENOUS

패키지 단위:

5ML

처방전 유형:

Prescription

치료 영역:

NEUROMUSCULAR BLOCKING AGENTS

제품 요약:

Active ingredient group (AIG) number: 0133260001; AHFS:

승인 상태:

CANCELLED PRE MARKET

승인 날짜:

2015-11-03

제품 특성 요약

_AJ-CISATRACURIUM (Cisatracurium Besylate Injection) Product Monograph
_
_Page 1 of 31 _
PRODUCT MONOGRAPH
PR
AJ-CISATRACURIUM
CISATRACURIUM BESYLATE INJECTION
SOLUTION FOR INJECTION
2 MG/ML CISATRACURIUM (AS CISATRACURIUM BESYLATE)
10 ML MULTIPLE DOSE VIAL
NON-DEPOLARIZING SKELETAL NEUROMUSCULAR BLOCKING AGENT
THIS DRUG SHOULD BE ADMINISTERED ONLY BY ADEQUATELY TRAINED
PROFESSIONALS FAMILIAR
WITH ITS ACTIONS, CHARACTERISTICS, AND HAZARDS.
AGILA JAMP CANADA INC.
1380 – 203 Newton Street
Boucherville, Quebec
Canada
J4B 5H2
DATE OF PREPARATION:
July 17, 2013
CONTROL NO.: 165928
_AJ-CISATRACURIUM (Cisatracurium Besylate Injection) Product Monograph
_
_Page 2 of 31 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................... 3
SUMMARY PRODUCT INFORMATION
................................................................................
3
INDICATIONS AND CLINICAL USE
......................................................................................
3
CONTRAINDICATIONS
............................................................................................................
3
WARNINGS AND PRECAUTIONS
..........................................................................................
4
ADVERSE REACTIONS
............................................................................................................
9
DRUG INTERACTIONS
..........................................................................................................
10
DOSAGE AND ADMINISTRATION
......................................................................................
11
ACTION AND CLINICAL PHARMACOLOGY
.....................................................................
16
STORAGE AND STABILITY
..................................................................................................
23
SPECIAL HANDLING INSTRUCTIONS
................................................................................
23
DOSAGE FORMS, COMPOSITION AND PACKAGING
......................